Medicare coverage of targeted disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) -- both under Medicare Advantage and in separate Part D plans -- is likely to leave many ...

How do dermatologists diagnose hidradenitis suppurativa? Hidradenitis suppurativa can look like other skin conditions, including acne, boils, or herpes. Dermatologists have the training needed to spot ...

Biologics help reduce symptoms and prevent flare-ups in Crohn’s disease. Biologics are made up of large molecules from living things. Monoclonal antibodies are a common type of biologic used for Crohn ...

MannKind announced the FDA approved an at-home furosemide self-injection for treatment of edema in adults with HF or chronic ...

Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth –– ARCALYST 2026 expected net ...

Since 1971, protection against measles, mumps, and rubella has been delivered in a single combined injection. A proposal to ...

- ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth- - ARCALYST 2026 expected net product revenue increased to $980 - $995 million- - KPL-387 ...

Acquisitions are expanding IonQ's technological capabilities. Management also highlighted the company's impressive organic growth. 10 stocks we like better than IonQ › Shares of IonQ (NYSE: IONQ) ...

– ARCALYST 2026 expected net product revenue increased to $980 - $995 million – – KPL-387 Phase 2 data demonstrated rapid and sustained reductions in pain and inflammation at 300 mg SC once-monthly, ...

aUniversity of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA ...